Business Context and Reporting Period
This Form 8-K was filed by Kura Oncology, Inc. on September 9, 2026, reporting events that occurred on September 8, 2026. The filing details the formation of a wholly owned subsidiary, Caspian Therapeutics, Inc. ("Caspian"), to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases.
Key Financial Metrics and Transaction Details
- Subsidiary Financing: Caspian completed a private Series A financing, issuing $50.0 million of Series A preferred stock.
- Parent Investment: Kura Oncology invested $4.3 million in the Series A Financing.
- Ownership Structure: Immediately following the financing, Kura Oncology's common stock and Caspian's Series A preferred stock comprised approximately 49.2% of Caspian's outstanding capital stock.
- Asset Contribution Reimbursement: Kura Oncology received a one-time reimbursement payment of up to $1.5 million for costs associated with maintaining assigned assets prior to closing.
Material Changes and Agreements
The filing reports the execution of three primary agreements on September 8, 2026:
- Contribution and License Agreement: Kura contributed rights to next-generation menin inhibitors (including compound KO-7246) and related intellectual property to Caspian in exchange for equity and the reimbursement payment. Caspian is solely responsible for development and commercialization in the diabetes and cardiometabolic field.
- Licensing Arrangements: Kura granted Caspian non-exclusive, royalty-free licenses under certain patents and data relating to ziftomenib for use in the Caspian field. Caspian granted Kura a reciprocal license for research and development purposes.
- Intercompany Services Agreement: Kura agreed to provide research, development, and administrative services to Caspian for fees. The agreement has an initial one-year term with automatic annual renewals unless terminated with 90 days' notice.
Guidance, Risks, and Contingencies
The filing does not provide updated financial guidance, revenue projections, or liquidity metrics for Kura Oncology. The primary risk disclosed relates to the negative covenants in the Contribution Agreement, which restrict both Kura and Caspian from exploiting menin inhibitors outside their respective fields for a specified period, subject to change of control exceptions.
Key Facts for Investor Verification
- Verify the identity of the other investors in Caspian's $50.0 million Series A Financing to understand the remaining 50.8% ownership structure.
- Confirm the specific valuation of Caspian Therapeutics implied by the $50.0 million raise and Kura's 49.2% stake.
- Review the terms of the Intercompany Services Agreement to assess potential ongoing revenue streams or cost burdens for Kura.
- Monitor the development progress of the assigned asset, KO-7246, now under Caspian's sole responsibility.